•
Sep 30, 2023

The Joint Q3 2023 Earnings Report

Reported financial results for the third quarter of 2023.

Key Takeaways

The Joint Corp. reported revenue of $29.5 million for Q3 2023, compared to $26.5 million in Q3 2022. The company experienced an operating loss of $898,000, a net loss of $716,000, or $0.05 per share, and an adjusted EBITDA of $2.9 million.

Revenue increased to $29.5 million, compared to $26.5 million in the third quarter of 2022.

Operating loss was $898,000, compared to operating income of $732,000 in the third quarter of 2022.

Net loss was $716,000, or $0.05 per share, compared to income of $731,000 or $0.05 per share in the third quarter of 2022.

Adjusted EBITDA was $2.9 million, compared to $3.1 million in the third quarter of 2022.

Total Revenue
$29.5M
Previous year: $26.6M
+10.8%
EPS
-$0.05
Previous year: $0.03
-266.7%
Gross Profit
$26.9M
Previous year: $24.1M
+11.4%
Cash and Equivalents
$16.1M
Previous year: $10.3M
+56.3%
Free Cash Flow
$2.7M
Previous year: $3.06M
-11.8%
Total Assets
$98.6M
Previous year: $89.5M
+10.1%

The Joint

The Joint

Forward Guidance

Management has reiterated the financial and clinic opening guidance for 2023.